Unveiling a Potential Brain Cancer Treatment: A Fungal Compound's Promise
In a groundbreaking development, MIT chemists have successfully synthesized a fungal compound, verticillin A, which has shown promising anticancer properties. This achievement, over 50 years in the making, offers new hope in the fight against brain cancer.
The Challenge of Complexity
Despite its similarity to other fungal compounds, verticillin A's complex structure posed a significant synthesis challenge. With just a couple of atoms differentiating it from its relatives, the compound's fragility and sensitivity made it a formidable task.
Professor Mohammad Movassaghi, an MIT chemist, explains, "The subtle structural changes greatly increase the difficulty of synthesis. But now, with advanced technology, we can not only create this compound for the first time but also design and study its variants."
A Promising Lead for Pediatric Brain Cancer
In tests on human cancer cells, a derivative of verticillin A demonstrated particular effectiveness against diffuse midline glioma, a type of pediatric brain cancer. While further testing is needed, this initial success offers a glimmer of hope for a disease with limited treatment options.
The Journey to Synthesis
The story of verticillin A's synthesis began in 1970 when researchers first isolated it from fungi. Its potential anticancer and antimicrobial properties intrigued scientists, but its complexity hindered progress.
In 2009, Movassaghi's lab made a breakthrough by synthesizing (+)-11,11'-dideoxyverticillin A, a similar fungal compound. However, the presence of two oxygen atoms in verticillin A presented a new challenge, requiring a complete rethink of the synthetic approach.
A Different Synthetic Sequence
The researchers had to change the order of bond-forming events to achieve the correct stereochemistry. Starting with beta-hydroxytryptophan, they added various chemical functional groups, ensuring the correct orientation. A critical step involved introducing a carbon-sulfur bond and a disulfide bond early on to control stereochemistry, but these sensitive bonds had to be protected to prevent breakdown.
Movassaghi emphasizes, "This dimerization process is particularly complex due to the dense array of functional groups and stereochemistry involved."
Killing Cancer Cells: The Mechanism
Once the synthesis was complete, the researchers generated derivatives of verticillin A. These derivatives were tested against various types of diffuse midline glioma (DMG) by researchers at Dana-Farber. The most susceptible DMG cell lines were those with high levels of the protein EZHIP, which plays a role in DNA methylation.
Associate Professor Jun Qi explains, "Identifying these potential targets is crucial for understanding the mechanism of action and optimizing these compounds for novel therapy development."
The most successful compounds in killing these cancer cells were N-sulfonylated derivatives, which increased DNA methylation, leading to programmed cell death. N-sulfonylation adds stability to the molecules.
The Future of Verticillin A Research
The Dana-Farber team is now working to validate the mechanism of action and test the compounds in animal models of pediatric brain cancers. They aim to fully evaluate the therapeutic potential of these molecules by integrating expertise in various fields, from chemistry and chemical biology to cancer biology and patient care.
Qi concludes, "Natural compounds are invaluable resources for drug discovery, and we aim to understand their functions broadly in other cancers."
And This Is the Part Most People Miss...
While the focus is often on the final product, it's the journey and the challenges overcome that make scientific breakthroughs possible. The story of verticillin A's synthesis is a testament to the power of persistence and innovation in scientific research.
What do you think? Is this fungal compound a potential game-changer for brain cancer treatment? Share your thoughts in the comments!
